# A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Study · id `cardio:ct-nct05706506` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05706506](<https://clinicaltrials.gov/study/NCT05706506>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05706506

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT05706506. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-08 (actual); primary completion 2023-10-31 (actual). Results posted on 2024-12-13.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Started: 2023-03-08 (actual) (ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Primary completion: 2023-10-31 (actual) (ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Completion: 2023-10-31 (actual) (ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Results first posted: 2024-12-13 (ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05706506, source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05706506-2024-12-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
- Condition: Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Tirzepatide
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 6be8f237d0fa8a011b7c08d3840f8ae511a6dcda92ba501e819c4716d98159ac
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
